[Endogenous biological retranslation in current clinical and biological studies].
The paper generalizes the results of research implemented within the framework of the methodological concept of the Endogenous Biological Retranslation (EBR) for the purpose of finding new data about the immune pathogenesis of multiple sclerosis (MS), whose mechanisms are related with violations of the EBR processes in the body. A possibility is considered to use the priming of interferon (INF) production, as an EBR variant, for evaluating the functioning of the INF system. The thus obtained materials prove convincingly that the experimental approaches, based on priming the blood cells to the IFN production, can be clinically used in the diagnosis and therapy of MS. A new effective combined IFN-therapy scheme for the disease in question was demonstrated. A set of criteria, which makes it possible to prescribe the INF preparations for MS patients with regard for an evaluated response degree of patients' blood cells to them and with regard for a prognosticated efficacy of an assumed treatment is offered. Possibilities of an individualized comprehensive therapy for MS by using the offered experimental approaches are discussed.
S B
SB
Cheknev
D000328:Adult; D000818:Animals; D001773:Blood Cells / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use; D016899:Interferon-beta / Q000276:immunology / Q000627:therapeutic use; D007371:Interferon-gamma / Q000276:immunology / Q000627:therapeutic use; D007372:Interferons / Q000172:deficiency / Q000276:immunology* / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D011379:Prognosis; D011994:Recombinant Proteins; D012106:Research
D016898:Interferon-alpha; D011994:Recombinant Proteins; D016899:Interferon-beta; D007371:Interferon-gamma; D007372:Interferons